Applied Clinical Trials
Industry Standard Research has recently published new research titled "Post-marketing Safety Market Dynamics," which deeply dives into the growth and decline of study conduct and outsourcing in the post-marketing safety arena.
Industry Standard Research has recently published new research titled "Post-marketing Safety Market Dynamics," which deeply dives into the growth and decline of study conduct and outsourcing in the post-marketing safety arena. As with much the company's research, a portion of the work was dedicated to exploring the attitudes and use of service providers in the space. Sponsors identified different types of service providers as "Best Fit," depending on the specific service. And the pattern of winners and losers is variable across all five services tested (Phase IV studies, Signal Management Activities, Risk Management Programs, EU QPPV Service, and Scientific Literature Searches).
However, in spite of their lagging position for signal management activities (and some of the others tested) sponsors continue to express a preference for using large CROs.
Large CROs were voted the best fit for non-interventional Phase IV studies.
What should be made of this dynamic? Why should a buyer prefer to use members of a group they believe are a poor fit for the service, relatively speaking?
Perhaps it is the old adage that "nobody gets fired for hiring IBM." But for our industry it's "nobody gets fired for hiring Quintiles/PPD/PAREXEL/Covance/ICON." Or perhaps in spite of a theoretical good fit, the scope of the work is outgrowing the specialists' capabilities. Your thoughts? Send them to info@ISRreports.com.
—Industry Standard Research,
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.